Clinical Trial Update: Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study with clinical endpoints comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN in chronic open-angle glaucoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Open-angle

Drugs mentioned

• Bimatoprost Ophthalmic Solution 0.01% (bimatoprost)
• Lumigan (bimatoprost)

Snippet

Sponsor: Mankind Pharma Limited | Conditions: Glaucoma, Open-Angle | Phase 3 | Status: COMPLETED